

A1
Amended. antagonist is contained in a formulation or medicament intended for administration in a quantity of 1 to 75 wt.%, preferably 5 to 50 wt.%, preferably 5 to 25 wt.%.

A2
Claim 18. (Amended) The process [Process] according to claim 17, characterized by [at least one of the features of claims 2 to 16] the features of claim 2.

A3
Claim 20. (Amended) The composition [Composition] or medicament according to claim 19, characterized by [at least one of the features of claims 7 to 16] the features of claim 7.

REMARKS

00E020-1690E56
Claims 1-20 are pending in the present application. The amendments do not add any new matter under 35 U.S.C. §132. The amendments have been made to remove multiple dependencies from the claims and to convert the use claims into method claim format. Accordingly, entry of the amendments prior to examination of the application is respectfully requested.

CONCLUSION

In view of the foregoing, Applicants respectfully request the Examiner to allow all claims pending in this application. If the Examiner has any questions or wishes to discuss this matter, the Examiner is welcomed to telephone the undersigned attorney.

ZENNER et al.

NATH & ASSOCIATES PLLC

Date: May 4, 2000
NATH & ASSOCIATES PLLC
1030th Street, NW - 6th Floor
Washington, D.C. 20005-1503
GMN:JLM:JBG:\AMENDpremPCT2

Gary M. Nath
Reg. No. 26,965
Customer No. 20529

[illegible]